1,360
Participants
Start Date
April 9, 2024
Primary Completion Date
January 1, 2026
Study Completion Date
January 1, 2026
Tirofiban
After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
Saline placebo
After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
RECRUITING
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Wuhan Central Hospital
OTHER
Zhongnan Hospital
OTHER
Renmin Hospital of Wuhan University
OTHER
Second Affiliated Hospital of Soochow University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Wuhan Hospital of Traditional Chinese Medicine
OTHER
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
OTHER
Huangshi Central Hospital
OTHER
The First Affiliated Hospital of Yangtze University
OTHER
The Fifth Hospital of Wuhan
OTHER
Wuhan Puren Hospital
OTHER
Xiangyang No.1 People's Hospital
OTHER
Xianning Central Hospital
OTHER
Hanyang University
OTHER
Wuhan Third Hospital
OTHER
Yichang Central People's Hospital
OTHER
Affiliated Hospital of Chengde Medical University
OTHER
Beijing Tiantan Hospital
OTHER
Nanyang Central Hospital
OTHER
Jingzhou Central Hospital
OTHER
Taihe Hospital
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Xiang Luo
OTHER